Title
Category
Credits
Event date
Cost
  • Oncology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths. For more than three decades, systemic platinum-based chemotherapy has been the standard first-line treatment for patients with inoperable or advanced metastatic bladder cancer.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Join Drs. Neal Shore, Gautam Jayram, and Nurse Tanya O’Neal as they discuss clinical considerations for managing immune-related adverse events that may occur at any time during therapy and, as of yet, there is no reliable means to predict who will develop them. If irAEs do develop, it is essential to arrive at an early diagnosis and use aggressive systemic corticosteroids when necessary to prevent life-threatening consequences.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
As the treatment paradigm for bladder cancer continuously evolves, all members of the oncology healthcare team must be equipped to evolve with it to ensure optimal patient care. With this evolution comes many questions for the bladder cancer treatment team. Join Drs. Neal Shore, Arjun Balar, Lidia Lopez, and Nurse Joanie Pfahl as they examine the new paradigm of bladder treatment using ICIs, and discuss the important role of each person on the treatment team.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond. Though trial data are still evolving, mounting evidence suggests a role for immunotherapy earlier in the disease spectrum, as front-line therapy for cisplatin-ineligible patients, and in combinatorial regimens in late-stage disease. Join Drs.
  • Cardiology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
$0.00
This adaptive educational activity is targeted to managed care professionals, physicians, and specialty pharmacists attending the 2021 Academy of Managed Care Pharmacy (AMCP) Annual Meeting. Activity attendees will be given the opportunity to virtually interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency (ID) management in the setting of comorbid heart failure (HF).
  • Cardiology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
04/16/2021
$0.00
This adaptive educational activity is targeted to managed care professionals, physicians, and specialty pharmacists attending the 2021 Academy of Managed Care Pharmacy (AMCP) Annual Meeting. Activity attendees will be given the opportunity to virtually interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency (ID) management in the setting of comorbid heart failure (HF).
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
04/23/2021
$0.00
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.Supported through an independent educational grant from AstraZeneca.
  • Oncology
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
04/29/2021
$0.00
This series will review the role of the B-cell receptor pathway in the treatment of B-cell malignancies and explore the latest safety and efficacy data for novel, oral agents such as BTK inhibitors, PI3K inhibitors, and BCL-2 inhibitors.Presented by Creative Educational Concepts, Inc. and accredited by the University of Cincinnati.Supported through independent educational grants from AstraZeneca and Janssen.
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
04/29/2021
$0.00
This Grand Rounds series is targeted to physician specialists in nephrology, cardiology, emergency medicine, and primary care, as well as pharmacists, nurses, nurse practitioners, and physician assistants who manage patients with ESRD.Supported through an independent educational grant from AstraZeneca.
  • Cardiology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
05/06/2021
$0.00
This Grand Rounds initiative is targeted to cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants. Designed to foster meaningful interprofessional and interdisciplinary collaboration, this accredited activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF).

Pages